Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

1 Oct 2016

Abstract excerpt

PURPOSE: Somatic mutations in the tyrosine kinase domain of human epidermal growth factor receptor 2 (HER2) may be an alternative mechanism to HER2 activation and can affect the sensitivity toward HER2-targeted therapies. We aimed to investigate the prevalence, clinicopathologic characteristics, and functional relevance of novel HER2 mutations in breast cancer. EXPERIMENTAL DESIGN: We performed Sanger sequencing...

Topics

Join the communities discussing this publication.

Advanced Breast Cancer Therapies
Cancer Treatment and Pharmacology
HER2/EGFR in Cancer Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 27697991
DOI: 10.1158/1078-0432.ccr-15-3036

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast CancerPMID 27697991Read ↗

Activating HER2 mutations in HER2 gene amplification negative breast cancer.Semantic proximity Read ↗

Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer.Semantic proximity Read ↗

Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in HER2-mutant breast cancerSemantic proximity Read ↗

Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature.Semantic proximity Read ↗

Activating HER2 mutations as emerging targets in multiple solid cancersSemantic proximity Read ↗

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read ↗

Rare HER2 L796P missense mutation promotes the growth and oncogenic signaling in breast cancer cells.Semantic proximity Read ↗

HER2 mutation as an emerging target in advanced breast cancer.Semantic proximity Read ↗

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast CancerSemantic proximity Read ↗

A review of HER2 overexpression and somatic mutations in cancers.Semantic proximity Read ↗

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.